BAW2881
|
|
|
- CAS号:
- 861875-60-7
- 英文名:
- NVP-BAW2881
- 英文别名:
- CS-2238;BAW2881;NVP-BAW2881;NVP-BAW2881 (BAW2881;BAW2881 (NVP-BAW2881);NVP-BAW2881, 10 mM in DMSO;BAW2881 (NVP-BAW2881) ，S8189;NVP-BAW2881;NVP-BAW-2881;;NVP-BAW 2881;6-((2-aminopyrimidin-4-yl)oxy)-N-(3-(trifluoromethyl)phenyl)-1-naphthamide;1-Naphthalenecarboxamide, 6-[(2-amino-4-pyrimidinyl)oxy]-N-[3-(trifluoromethyl)phenyl]-
- 中文名:
- BAW2881
- 中文别名:
- 化合物BAW2881;化合物BAW2881,10 MM DMSO 溶液;BAW2881 (NVP-BAW2881) ,S8189;NVP-BAW2881 (BAW2881;BAW-2881);6-((2-氨基-4-嘧啶基)氧基)-N-(3-(三氟甲基)苯基)-1-萘甲酰胺
- CBNumber:
- CB93133229
- 分子式:
- C22H15F3N4O2
- 分子量:
- 424.38
- MOL File:
- 861875-60-7.mol
|
|
|
BAW2881化学性质
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
≥42.4 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
-
|
-
形态:
-
solid
-
|
-
颜色:
-
White to off-white
-
|
BAW2881性质、用途与生产工艺
BAW2881 (NVP-BAW2881)是一种新型的VEGFR酪氨酸激酶抑制剂。在1.0-4.3 nM浓度下能有效地抑制VEGFR1-3；在45-72 nM的浓度下，抑制PDGFRβ, c-Kit和RET (c-RET)。
| Target | Value |
hVEGFR2
(Cell-free assay)
|
9 nM
|
C-Raf-1
(Cell-free assay)
|
24 nM
|
B-RAFV599E
(Cell-free assay)
|
76 nM
|
c-Abl
(Cell-free assay)
|
99 nM
|
mVEGF2
(Cell-free assay)
|
165 nM
|
体外实验证明NVP-BAW2881能够抑制人脐静脉内皮细胞和淋巴管内皮细胞的增殖、迁移以及小管生成。
NVP-BAW2881能够靶向鼠源、猪源和人源VEGFR2的酪氨酸激酶区域。它能通过口服或局部施用，但还未在人类中进行试验。在VEGF-A转基因小鼠的体内试验中，口服或局部NVP-BAW2881给药能减少耳部皮肤的类似牛皮藓的炎症。处理过的小鼠的皮肤损伤处会减少白细胞浸润、减少表皮增生、正常表皮角化细胞分化以及较少的血管异常。NVP-BAW2881处理过的小鼠的血管变小、数量减少。相较于对照组，实验组小鼠的耳肿胀、皮肤炎症、淋巴结肿大、皮肤红斑得到改善。虽然两种给药途径都有效（口服和局部施用），但全身性用药比局部给药更为强效。局部施用NVP-BAW2881在小鼠和家猪皮肤中，能减少VEGF-A诱导的血管通透性。
BAW2881
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2025/09/19 | S8189 | BAW2881
BAW2881 (NVP-BAW2881) | 861875-60-7 | 5mg | 1122.22元 |
| 2025/09/19 | S8189 | BAW2881
BAW2881 (NVP-BAW2881) | 861875-60-7 | 25mg | 4070.85元 |
861875-60-7, BAW2881 相关搜索:
- 抑制剂
- 药靶配体
- 标准品
- BAW2881 (NVP-BAW2881) ,S8189
- NVP-BAW2881 (BAW2881;BAW-2881)
- 化合物BAW2881,10 MM DMSO 溶液
- 6-((2-氨基-4-嘧啶基)氧基)-N-(3-(三氟甲基)苯基)-1-萘甲酰胺
- 化合物BAW2881
- 861875-60-7
- BAW2881 (NVP-BAW2881) ，S8189
- NVP-BAW2881 (BAW2881
- NVP-BAW2881, 10 mM in DMSO
- NVPBAW2881,inhibit,BAW 2881,NVP BAW2881,Vascular endothelial growth factor receptor,VEGFR,Inhibitor,NVP-BAW2881,BAW-2881,NVP-BAW-2881
- 1-Naphthalenecarboxamide, 6-[(2-amino-4-pyrimidinyl)oxy]-N-[3-(trifluoromethyl)phenyl]-
- NVP-BAW2881;NVP-BAW-2881;;NVP-BAW 2881
- CS-2238
- 6-(2-amino-pyrimidin-4-yloxy)naphthalene-1-carboxylic acid (3-trifluoromethyl phenyl)amide
- 6-((2-aminopyrimidin-4-yl)oxy)-N-(3-(trifluoromethyl)phenyl)-1-naphthamide
- BAW2881 (NVP-BAW2881)
- BAW2881
- NVP-BAW2881